Logo image of XRAY

DENTSPLY SIRONA INC (XRAY) Stock Fundamental Analysis

NASDAQ:XRAY - Nasdaq - US24906P1093 - Common Stock - Currency: USD

16.54  +0.66 (+4.16%)

After market: 16.54 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to XRAY. XRAY was compared to 187 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of XRAY while its profitability can be described as average. XRAY has a bad growth rate and is valued cheaply.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

XRAY had positive earnings in the past year.
XRAY had a positive operating cash flow in the past year.
XRAY had negative earnings in 4 of the past 5 years.
In the past 5 years XRAY always reported a positive cash flow from operatings.
XRAY Yearly Net Income VS EBIT VS OCF VS FCFXRAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B -1.5B

1.2 Ratios

With a Return On Assets value of -15.01%, XRAY perfoms like the industry average, outperforming 55.08% of the companies in the same industry.
With a Return On Equity value of -45.17%, XRAY perfoms like the industry average, outperforming 50.27% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 4.66%, XRAY is in the better half of the industry, outperforming 78.07% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for XRAY is below the industry average of 7.89%.
The last Return On Invested Capital (4.66%) for XRAY is above the 3 year average (4.11%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -15.01%
ROE -45.17%
ROIC 4.66%
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
XRAY Yearly ROA, ROE, ROICXRAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30 -40

1.3 Margins

XRAY has a Operating Margin of 6.75%. This is in the better half of the industry: XRAY outperforms 75.40% of its industry peers.
In the last couple of years the Operating Margin of XRAY has declined.
With a Gross Margin value of 51.84%, XRAY perfoms like the industry average, outperforming 46.52% of the companies in the same industry.
In the last couple of years the Gross Margin of XRAY has remained more or less at the same level.
Industry RankSector Rank
OM 6.75%
PM (TTM) N/A
GM 51.84%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
XRAY Yearly Profit, Operating, Gross MarginsXRAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XRAY is destroying value.
Compared to 1 year ago, XRAY has less shares outstanding
Compared to 5 years ago, XRAY has less shares outstanding
Compared to 1 year ago, XRAY has a worse debt to assets ratio.
XRAY Yearly Shares OutstandingXRAY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
XRAY Yearly Total Debt VS Total AssetsXRAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

XRAY has an Altman-Z score of 1.08. This is a bad value and indicates that XRAY is not financially healthy and even has some risk of bankruptcy.
XRAY has a Altman-Z score of 1.08. This is comparable to the rest of the industry: XRAY outperforms 50.27% of its industry peers.
XRAY has a debt to FCF ratio of 8.40. This is a slightly negative value and a sign of low solvency as XRAY would need 8.40 years to pay back of all of its debts.
The Debt to FCF ratio of XRAY (8.40) is better than 76.47% of its industry peers.
A Debt/Equity ratio of 0.79 indicates that XRAY is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.79, XRAY is not doing good in the industry: 73.80% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF 8.4
Altman-Z 1.08
ROIC/WACC0.6
WACC7.77%
XRAY Yearly LT Debt VS Equity VS FCFXRAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

A Current Ratio of 1.10 indicates that XRAY should not have too much problems paying its short term obligations.
The Current ratio of XRAY (1.10) is worse than 87.17% of its industry peers.
XRAY has a Quick Ratio of 1.10. This is a bad value and indicates that XRAY is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.76, XRAY is not doing good in the industry: 87.70% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.1
Quick Ratio 0.76
XRAY Yearly Current Assets VS Current LiabilitesXRAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

3

3. Growth

3.1 Past

The earnings per share for XRAY have decreased by -9.68% in the last year.
Measured over the past years, XRAY shows a decrease in Earnings Per Share. The EPS has been decreasing by -7.38% on average per year.
XRAY shows a decrease in Revenue. In the last year, the revenue decreased by -5.61%.
XRAY shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.17% yearly.
EPS 1Y (TTM)-9.68%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%2.38%
Revenue 1Y (TTM)-5.61%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-7.76%

3.2 Future

Based on estimates for the next years, XRAY will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.35% on average per year.
XRAY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.07% yearly.
EPS Next Y15.88%
EPS Next 2Y11.8%
EPS Next 3Y11.11%
EPS Next 5Y9.35%
Revenue Next Year-4.12%
Revenue Next 2Y-0.81%
Revenue Next 3Y0.45%
Revenue Next 5Y1.07%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XRAY Yearly Revenue VS EstimatesXRAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B 4B
XRAY Yearly EPS VS EstimatesXRAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.5 1 1.5 2 2.5

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 9.85, the valuation of XRAY can be described as very reasonable.
XRAY's Price/Earnings ratio is rather cheap when compared to the industry. XRAY is cheaper than 95.19% of the companies in the same industry.
XRAY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.21.
With a Price/Forward Earnings ratio of 7.92, the valuation of XRAY can be described as very cheap.
Based on the Price/Forward Earnings ratio, XRAY is valued cheaply inside the industry as 95.72% of the companies are valued more expensively.
XRAY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.70.
Industry RankSector Rank
PE 9.85
Fwd PE 7.92
XRAY Price Earnings VS Forward Price EarningsXRAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

XRAY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. XRAY is cheaper than 93.05% of the companies in the same industry.
XRAY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. XRAY is cheaper than 95.19% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.86
EV/EBITDA 8.83
XRAY Per share dataXRAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

XRAY's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.62
PEG (5Y)N/A
EPS Next 2Y11.8%
EPS Next 3Y11.11%

6

5. Dividend

5.1 Amount

XRAY has a Yearly Dividend Yield of 4.00%.
Compared to an average industry Dividend Yield of 1.82, XRAY pays a better dividend. On top of this XRAY pays more dividend than 98.93% of the companies listed in the same industry.
XRAY's Dividend Yield is rather good when compared to the S&P500 average which is at 2.42.
Industry RankSector Rank
Dividend Yield 4%

5.2 History

On average, the dividend of XRAY grows each year by 11.21%, which is quite nice.
XRAY has been paying a dividend for at least 10 years, so it has a reliable track record.
XRAY has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)11.21%
Div Incr Years6
Div Non Decr Years30
XRAY Yearly Dividends per shareXRAY Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

XRAY has negative earnings and hence a negative payout ratio. The dividend may be in danger.
The dividend of XRAY is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP-14.21%
EPS Next 2Y11.8%
EPS Next 3Y11.11%
XRAY Yearly Income VS Free CF VS DividendXRAY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B -1.5B

DENTSPLY SIRONA INC

NASDAQ:XRAY (7/1/2025, 9:17:50 PM)

After market: 16.54 0 (0%)

16.54

+0.66 (+4.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/bmo
Earnings (Next)07-29 2025-07-29/bmo
Inst Owners104.5%
Inst Owner Change0.95%
Ins Owners0.33%
Ins Owner Change6.93%
Market Cap3.30B
Analysts70.43
Price Target18.4 (11.25%)
Short Float %4.22%
Short Ratio3.05
Dividend
Industry RankSector Rank
Dividend Yield 4%
Yearly Dividend0.62
Dividend Growth(5Y)11.21%
DP-14.21%
Div Incr Years6
Div Non Decr Years30
Ex-Date06-27 2025-06-27 (0.16)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.42%
Min EPS beat(2)-40.52%
Max EPS beat(2)45.37%
EPS beat(4)2
Avg EPS beat(4)1.53%
Min EPS beat(4)-40.52%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)2.46%
EPS beat(12)6
Avg EPS beat(12)5.25%
EPS beat(16)8
Avg EPS beat(16)3.68%
Revenue beat(2)1
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-3.62%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-1.66%
Min Revenue beat(4)-3.62%
Max Revenue beat(4)0.77%
Revenue beat(8)3
Avg Revenue beat(8)-1.57%
Revenue beat(12)5
Avg Revenue beat(12)-1.53%
Revenue beat(16)6
Avg Revenue beat(16)-1.71%
PT rev (1m)0.46%
PT rev (3m)-9.03%
EPS NQ rev (1m)-0.24%
EPS NQ rev (3m)10.68%
EPS NY rev (1m)2.34%
EPS NY rev (3m)4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.88%
Revenue NY rev (1m)0.4%
Revenue NY rev (3m)1.33%
Valuation
Industry RankSector Rank
PE 9.85
Fwd PE 7.92
P/S 0.89
P/FCF 11.86
P/OCF 7.44
P/B 1.64
P/tB N/A
EV/EBITDA 8.83
EPS(TTM)1.68
EY10.16%
EPS(NY)2.09
Fwd EY12.62%
FCF(TTM)1.39
FCFY8.43%
OCF(TTM)2.22
OCFY13.44%
SpS18.66
BVpS10.09
TBVpS-4.18
PEG (NY)0.62
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.01%
ROE -45.17%
ROCE 5.9%
ROIC 4.66%
ROICexc 5.14%
ROICexgc 19.54%
OM 6.75%
PM (TTM) N/A
GM 51.84%
FCFM 7.48%
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
ROICexc(3y)4.36%
ROICexc(5y)4.5%
ROICexgc(3y)15.64%
ROICexgc(5y)20.94%
ROCE(3y)5.38%
ROCE(5y)5.49%
ROICexcg growth 3Y-31.16%
ROICexcg growth 5Y-12.42%
ROICexc growth 3Y-13.44%
ROICexc growth 5Y-4.44%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
F-Score3
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF 8.4
Debt/EBITDA 2.69
Cap/Depr 48.25%
Cap/Sales 4.44%
Interest Coverage 250
Cash Conversion 74.7%
Profit Quality N/A
Current Ratio 1.1
Quick Ratio 0.76
Altman-Z 1.08
F-Score3
WACC7.77%
ROIC/WACC0.6
Cap/Depr(3y)46.81%
Cap/Depr(5y)41.51%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.68%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%2.38%
EPS Next Y15.88%
EPS Next 2Y11.8%
EPS Next 3Y11.11%
EPS Next 5Y9.35%
Revenue 1Y (TTM)-5.61%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-7.76%
Revenue Next Year-4.12%
Revenue Next 2Y-0.81%
Revenue Next 3Y0.45%
Revenue Next 5Y1.07%
EBIT growth 1Y-11.93%
EBIT growth 3Y-28.45%
EBIT growth 5Y-13.75%
EBIT Next Year49.44%
EBIT Next 3Y19.3%
EBIT Next 5Y10.5%
FCF growth 1Y7.34%
FCF growth 3Y-18.29%
FCF growth 5Y-11.45%
OCF growth 1Y9.93%
OCF growth 3Y-11.14%
OCF growth 5Y-6.32%